

Nasopharyngitis (Common Cold) pipeline Research Monitor, 2020- Drugs, Companies, Clinical Trials, R&D pipeline updates, status and outlook

<https://marketpublishers.com/r/NC012C05148BEN.html>

Date: July 2020

Pages: 50

Price: US\$ 1,599.00 (Single User License)

ID: NC012C05148BEN

Abstracts

2020 Nasopharyngitis (Common Cold) PIPELINE HIGHLIGHTS

Nasopharyngitis (Common Cold) is one of the widely researched conditions during 2020 with 7 companies actively focusing on realizing pipeline's potential. Development of Nasopharyngitis (Common Cold) medicines is identified as integral to the strategy of the majority of companies operating in the industry.

Global Nasopharyngitis (Common Cold) market presents promising new product pipeline with NME Projects, pivotal trials, and rapidly phase-advancing therapeutic candidates. Increasing number of companies are assessing the feasibility of developing treatment options for Nasopharyngitis (Common Cold).

Good progress is anticipated during 2020 and 2021 with Nasopharyngitis (Common Cold) pipeline molecules advancing from pre-clinical investigation to completion of advanced Phase clinical trials. Nasopharyngitis (Common Cold) pipeline continues to expand and progress with novel mechanisms and diverse routes of administration being tested by companies.

Nasopharyngitis (Common Cold) DRUG DEVELOPMENT PIPELINE OVERVIEW

The "Nasopharyngitis (Common Cold) pipeline Research Monitor, 2020" report is an analytical research study on the progress achieved by pipeline companies during the year along with its historical development, current status, and outlook.

This Nasopharyngitis (Common Cold) pipeline review explores high-potential early to late-stage pipeline projects with a continued focus on new insights, accelerated processes, and pipeline progression.

The competitive intelligence report on Nasopharyngitis (Common Cold) presents detailed insights into therapeutic drug pipeline development, industry news, deals, and

analysis across the length and breadth of the Nasopharyngitis (Common Cold) pipeline. Information on R&D pipeline updates, results of key clinical trials are also included in the report.

Nasopharyngitis (Common Cold) DRUG PROFILES

Nasopharyngitis (Common Cold) development pipeline including projects in early- and late-stage development are detailed in the report. Details of clinical trial data and submissions to regulatory authorities are also provided. For the drug candidates included in the report, the following information is provided-

Current Status of Development including phase advancements, regulatory approvals of phases, acquisitions, licensing and technology transfers, product launches in various markets, and others.

Phase of development

Mechanism of Action

Route of Administration

Companies involved including originator, licensing companies, developer, investors, and others

New molecular entity details

Orphan drug designation and other special status provided by regulators

Nasopharyngitis (Common Cold) COMPANY PROFILES

Both small size and large size pharmaceutical companies are investing their resources in Nasopharyngitis (Common Cold) drug development operations. Further, financial institutions are extending support to small pharmaceutical companies, universities, and other researchers for the development of treatment of Nasopharyngitis (Common Cold). Partnerships and acquisitions are also increasingly observed in the pipeline.

This research report presents an analysis of 7 Nasopharyngitis (Common Cold) companies including company overview, key snapshot, contact information, and their strategies on accelerating Nasopharyngitis (Common Cold) pipeline development. Mid-stage and early portfolios of these companies are analyzed in detail in the report.

Companies analyzed in the report include- Charleston Laboratories Inc, Firebrick Pharma Pty Ltd , Karo Pharma AB, Orbis Biosciences Inc, Pfizer Inc, Sanotize Research And Development Corp, Tris Pharma Inc

REASONS TO BUY

The current market conditions are forcing companies and investors worldwide to prioritize their investments and accelerate pipeline candidates only through careful quantitative assessment.

This research work assists decision makers in pharmaceutical companies towards successful pipeline development through critically evaluated pipeline data

Buyers can identify most promising drug candidates for treatment of Nasopharyngitis (Common Cold)

It allows users to strengthen their pipeline through acquisitions, licensing and collaborations

Users can estimate possible delays in the delivery of pipeline or launch of new products

Stay ahead of competition through understanding their pipeline progression, strategies and outlook

The report details all the pipeline candidates under investigation in various stages of development from Phase I through to Phase III to enable business development managers to understand the impact of new launches.

Optimize your licensing and technology transfer strategies through identification of prospect partners

Contents

1. INTRODUCTION TO NASOPHARYNGITIS (COMMON COLD)

- 1.1 Nasopharyngitis (Common Cold)- Disease overview
- 1.2 Nasopharyngitis (Common Cold)- Market Size
- 1.3 Nasopharyngitis (Common Cold)- Companies Involved

2. NASOPHARYNGITIS (COMMON COLD) PIPELINE SNAPSHOT- 2020

- 2.1 Nasopharyngitis (Common Cold) Pipeline by Phase
- 2.2 Nasopharyngitis (Common Cold) Pipeline by Mechanism of Action
- 2.3 Nasopharyngitis (Common Cold) Pipeline by Route of Administration
- 2.4 Nasopharyngitis (Common Cold) Pipeline- New Molecular Entities
- 2.5 Nasopharyngitis (Common Cold) Pipeline- Orphan Drug Designation/ Special Designation

3. NASOPHARYNGITIS (COMMON COLD) DRUG PROFILES

- 3.1 Current Status
- 3.2 Nasopharyngitis (Common Cold) Drug Snapshot
- 3.3 Nasopharyngitis (Common Cold) Therapeutic Candidates- Originator/Licensor
- 3.4 Route of Administration
- 3.5 Mechanism of Action
- 3.6 NME
- 4.1 Charleston Laboratories Inc Nasopharyngitis (Common Cold) Pipeline Insights and Clinical Trials
- 4.2 Firebrick Pharma Pty Ltd Nasopharyngitis (Common Cold) Pipeline Insights and Clinical Trials
- 4.3 Karo Pharma AB Nasopharyngitis (Common Cold) Pipeline Insights and Clinical Trials
- 4.4 Orbis Biosciences Inc Nasopharyngitis (Common Cold) Pipeline Insights and Clinical Trials
- 4.5 Pfizer Inc Nasopharyngitis (Common Cold) Pipeline Insights and Clinical Trials
- 4.6 Sanotize Research And Development Corp Nasopharyngitis (Common Cold) Pipeline Insights and Clinical Trials
- 4.7 Tris Pharma Inc Nasopharyngitis (Common Cold) Pipeline Insights and Clinical Trials

5. NASOPHARYNGITIS (COMMON COLD) MARKET NEWS AND UPDATES

6. APPENDIX

6.1 Sources and Methodology

6.2 Contact Information

I would like to order

Product name: Nasopharyngitis (Common Cold) pipeline Research Monitor, 2020- Drugs, Companies, Clinical Trials, R&D pipeline updates, status and outlook

Product link: <https://marketpublishers.com/r/NC012C05148BEN.html>

Price: US\$ 1,599.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/NC012C05148BEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

